

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/076,306
		Filing Date	February 12, 2002
		First Named Inventor	Hellstrand, et al.
		Art Unit	1642
(Multiple sheets used when necessary)		Examiner	Holleran, Anne L.
SHEET 1 OF 1		JAN 07 2005 U.S. PATENT & TRADEMARK OFFICE	
		Attorney Docket No.	MAXIM.026C3

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
ALH	1	5,508,031	04-16-1996	Zimmerman et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
					T ¹

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ¹

S:\DOCS\MKD\MKD-4817.DOC\010305

Examiner Signature	<i>Anne L. Holleran</i>	Date Considered	4/5/2005
--------------------	-------------------------	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

COPY
SHE.

SHEET 1 OF 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MAXIM.28C3	APPLICATION NO. Unknown 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		 APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)			
		FILING DATE February 12, 2002	GROUP Unknown 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
A/H	5,348,739	09-1994	Hellstrand et al			

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PLT	JP 7-185582	08/27/85	Japan (with English translation in 15 pages)				
PLT	WO 83/24144	12/09/83	Patent Cooperation Treaty				
	0 247 613 A2	12/02/87	European Patent Office				

**EXAMINER
INITIALS** **OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

A211	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
A211	Abrams, et al., "High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
Duplicate	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN-, Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor-, and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
Duplicate	Abrams, et al., "Compared Mechanisms of Tumor Cytolysis by Human Natural Killer Cells and Activated Polymorphonuclear Leukocytes," <i>The Journal of Immunology</i> 132: No. 6, 3192-3196, June 1984.
Duplicate	Abrams, et al., "High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma," <i>Journal of the National Cancer Institute</i> , 82: No. 14, 1202-1206, July 18, 1990.
A211	Alam, et al., "Comparative Effect of Recombinant IL-1, -2, -3, -4, and -6, IFN-, Granulocyte-Macrophage-Colony-Stimulating Factor, Tumor Necrosis Factor-, and Histamine-Releasing Factors on the Secretion of Histamine From Basophils," <i>The Journal of Immunology</i> , 142: No. 10, 3431-3435, May 18, 1989.
A211	Baker, et al., "Chondrocyte Antioxidant Defenses: The Roles of Catalase and Glutathione Peroxidase in Protection Against H ₂ O ₂ Dependent Inhibition of Proteoglycan Biosynthesis," <i>The Journal of Rheumatology</i> , 15: No. 4, 670-677, 1988.
A211	Barna, et al., "Tumor-Enhancing Effects of Cimetidine," <i>Oncology</i> , 40: 43-45, (1983).
A211	Beer, et al., The Influence of Histamine on Immune and Inflammatory Responses, <i>Advances in Immunology</i> , 35: 209-268 (1984).

EXAMINER Mr. L. E. K. Larson

DATE CONSIDERED

4/14/05

***EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.**

JAN 07 2005

SHEET 2 OF 8

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM 28C3	APPLICATION NO. Unknown 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
MM	Brune, et al., "Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia," <i>British Journal of Haematology</i> , 92:620-626 (1996).
MM	Budd, et al., "Phase I Trial of High-Dose Bolus Interleukin-2 and Interferon Alfa-2a in Patients With Metastatic Malignancy," <i>Journal of Clinical Oncology</i> , 10: No. 5, 804-809, May 1992.
MM	Burtin, et al., "Clinical Improvement in Advanced Cancer Disease After Treatment Combining Histamine and H2-Antihistaminics" (Ranitidine or Cimetidine), Accepted June 1987.
MM	Burtin, et al., "The Influence of Intraperitoneal Injections of Histamine on Tumour Growth in Fibrosarcoma-Bearing Mice", <i>Cancer Letters</i> , 12: 195-201, (1981).
MM	Chaudhri, et al., "Antioxidants Inhibit Proliferation and Cell Surface Expression of Receptors for Interleukin-2 and Transferrin in T Lymphocytes Stimulated with Phorbol Myristate Acetate and Ionomycin" <i>Cellular Immunology</i> , 115:204-213 (1988).
MM	Chehimi, et al., "Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from Both Healthy Donors and Human Immunodeficiency Virus-infected Patients," <i>Journal of Experimental Medicine</i> , 175: 789-796, March 1992.
MM	Ching, et al., "In vitro Methods for Screening Agents with an Indirect Mechanism of Antitumour Activity: Xanthenone Analogues of Flavone Acetic Acid," <i>Eur. J. Cancer</i> , 27: No. 12, 1684-1689, 1991.
MM	Ching, et al., "Induction of Natural Killer Activity by Xanthenone Analogues of Flavone Acetic Acid: Relation with Antitumour Activity," <i>Eur. J. Cancer</i> , 27: No. 1, 79-83, 1991.
MM	Damia, et al., "Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells," <i>Cancer Immunol Immunother</i> , 32: 241-244, 1990.
MM	Davies, et al., "Interactions between human monocytes and tumor cells. Monocytes can either enhance or inhibit the growth and survival of K562 Cells," November 1991.
MM	Dempsey, et al., "The Differential Effects of Human Leukocytic Pyrogen/Lymphocyte-Activating Factor, T Cell Growth Factor, and Interferon on Human Natural Killer Activity," <i>The Journal of Immunology</i> , May 17, 1982.
MM	Dillman, et al., "Continuous Interleukin-2 and Lymphokine-Activated Killer Cells for Advanced Cancer: A National Biotherapy Study Group Trial," <i>Journal of Clinical Oncology</i> , 9: No. 7, 1233-1240, July 1991.
MM	Dilman, et al., "Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated with Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group Trial," <i>Journal of the National Cancer Institute</i> , 82: No. 16, 1345-1348, August 15, 1990.
MM	Dohilstens, et al., "Histamine Inhibits Interferon- Production via Suppression of Interleukin 2 Synthesis," <i>Cellular Immunology</i> , 101: 493-501, 1986.
MM	Dröge, et al., "Effect of Reactive Oxygen Intermediates and Antioxidants on Proliferation and Function of T Lymphocytes" <i>Methods in Enzymology</i> , 234:135-151 (1994).
MM	Dröge, et al., "Histamine Augments Interleukin-2 Production and the Activation of Cytotoxic T Lymphocytes," <i>Immunopharmacology</i> , 11: 1-6, 1986.
MM	Dutcher, et al., "A Phase II Study of High-Dose Continuous Infusion Interleukin-2 With Lymphokine-Activated Killer Cells in Patients With Metastatic Melanoma," <i>Journal of Clinical Oncology</i> , 9: No. 4, 641-648, April 1991..

EXAMINER	One C. Heller	DATE CONSIDERED	4/14/2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

JAN 07 2005

SHEET 3 OF 6

FORM PTO-1448 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY/BOCKET NO. ACQUAM 28C3	APPLICATION NO. Unknown 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown

Best Available Copy

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Arth	Duwe, et al., "Natural Killer Cell-Mediated Lysis Involves an Hydroxyl Radical-Dependent Step," <i>The Journal of Immunology</i> , 134: No. 4, 2637-2644, April 1985.
Arth	El-Hag, et al., "Down-Regulation of Human Natural Killer Activity Against Tumors by the Neutrophil Myeloperoxidase System and Hydrogen Peroxide," <i>The Journal of Immunology</i> 133: No. 6, 3291-3297, December 1984.
Arth attached	Froelich, et al., "Induction of lymphokine activated killer cells in serum-free medium" <i>Journal of Immunological Methods</i> , 86:205-211, No. 2 (1986).
Arth	Galligioni, "Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with Flavone acetic acid (FAA)," <i>Annals of Oncology</i> , 2: 145-150, 1991.
Arth attached	Hellstrand, "Biogenic Amines in the Regulation of Human Natural Killer Cell Cytotoxicity," 1987.
Arth	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
Arth	Hellstrand, et al., "A Cell-to-Cell Mediated Interaction Involving Monocytes and NonT/CD16 ⁺ Natural Killer (NK) Cells is Required for Histamine H ₂ -Receptor-Mediated NK-Cell Activation," <i>Scand J. Immunol.</i> , 31: 631-644, 1990.
Arth	Hellstrand, et al., "Cell-to-Cell Mediated Inhibition of Natural Killer Cell Proliferation by Monocytes and its Regulation by Histamine H ₂ -Receptors," <i>Scand J. Immunol.</i> , 34: 741-752, 1991..
Arth	Hellstrand, et al., "Differential Effects of Histamine Receptor Antagonists on Human Natural Killer Cell Activity," <i>Int. Archs Allergy appl. Immunology</i> , 84: 247-255, 1987.
Arth	Hellstrand, et al., "Enhancement of Human Natural Killer Cell Cytotoxicity by Serotonin: Role of Non-T/CD16 ⁺ NK Cells, Accessory Monocytes, and 5-HT _{1A} Receptors," <i>Cellular Immunology</i> , 127: 199-214, 1990.
Arth	Hellstrand, et al., "Histamine H ₂ -Receptor-Mediated Regulation of Human Natural Killer Cell Activity," <i>The Journal of Immunology</i> , 137: No. 2, July 15, 1986.
Arth	Hellstrand, et al., "Monocyte-Induced Down-Modulation of CD16 and CD56 Antigens on Human Natural Killer Cells and its Regulation by Histamine H ₂ -Receptors," <i>Cellular Immunology</i> , 138: 44-45, 1991..
Arth	Hellstrand, et al., "Monocyte-Mediated Suppression of IL-2-Induced NK-Cell Activation," <i>Scand J. Immunol.</i> , 32: 183-192, 1990.
Arth	Hellstrand, et al., "Regulation of the Natural Killer Cell Response to Interferon- by Biogenic Amines," <i>Journal of Interferon Research</i> , 12: 199-206, 1992.
Arth	Hellstrand, et al., "Role of Histamine in Natural Killer Cell-Mediated Resistance Against Tumor Cells," <i>The Journal of Immunology</i> , 145: No. 12, December 15, 1990.
Arth	Hellstrand, et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity," <i>The Journal of Immunology</i> , 139: No. 3, August 1, 1987
Arth	Hellstrand, et al., "Serotonergic 5-HT _{1A} Receptors Regulate a Cell Contact-Mediated Interaction between Natural Killer Cells and Monocytes," <i>Scand J. Immunol.</i> , 37: 7-18, 1993
Arth duplicate	Hellstrand, et al., "Histaminergic Regulation of NK Cells" <i>Journal of Immunology</i> , 153:4940-4947, No. 11 (1994).
Arth	Hellstrand, et al., "Suppression of human natural killer cell cytotoxicity by interleukin-2," <i>Clin. Exp. Immunol.</i> , 77: 410-416, 1989

EXAMINER	Arth Hellstrand	DATE CONSIDERED	4/14/05
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 808; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

JAN 07 2005

SHEET 4 OF 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MAXX/28C3	APPLICATION NO. Unknown 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Att	Hellstrand, et al., "Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2," <i>Int. Arch. Allergy Appl. Immunology</i> , 92: 379-389, 1990.
Att Attached	Histamine augments interleukin-2 production and the activation of cytotoxic T lymphocytes. <i>Chemical Abstracts</i> , 104: Number 146898m, page 146891, <i>abstract of Dvorak, et al., Immunotherapy</i> . 11(1986)1-6.
Att	Hornung, et al., "Augmentation of Natural Killer Activity, Induction of IFN and Development Tumor Immunity During the Successful Treatment of Established Murine Renal Cancer Using Flavone Acetic Acid and IL-2," <i>The Journal of Immunology</i> , 141: No. 10, 3671-3679, November 15, 1988.
Att	Huwylter, et al., "Effect of Ascorbic Acid on Human Natural Killer Cells," <i>Immunology Letters</i> , 10: 173-176, 1985.
Att	Ilison, et al., "A Phase II Trial of Interleukin-2 and Interferon Alfa-2a in Patients With Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1124-1130, July 1992.
Att	Kendall A. Smith, "Interleukin-2: Inception, Impact, and Implications," <i>Science</i> , 240: 1169-1176, May 27, 1988.
Att	Kessel, et al., "Cytotoxicity by human adherent cells: oxygen-dependent and -independent cytotoxic reactions by different cell populations," <i>Immunology</i> , 58: 291-296, 1986.
Att	Khoo, et al., "Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2," <i>Clin. Exp. Metastasis</i> , 10: 239-252, 1992.
Att	Kriegel, et al., "enal Cell Carcinoma: Treatment With Recombinant Interleukin-2 Plus Beta-Interferon," <i>Journal of Clinical Oncology</i> , 8: No. 3, 460-467, March 1990.
Att	Lasek, et al., "Potentiation of antitumor effects of tumor necrosis factor α and interferon (by macrophage-colony-stimulating factor in a MnB16 melanoma model in mice" <i>Cancer Immunol Immunother</i> 40:315-321 (1995).
Att	Lespinatas, et al., "Enhancement by serotonin of intra-tumour penetration of spleen cells," <i>Br. J. Cancer</i> , 50: 545-547, (1984).
Att Attached	Los, et al., "Hydrogen peroxide as a potent activator of T lymphocyte functions" <i>Eur. Journal of Immunology</i> , 25:159-165 (1995).
Att	Lotze, et al., "Interleukin 2 as a Pharmacologic Reagent, Chapter 12 from the National Institutes of Health," October 28, 1988.
Att DUK	Malech, et al., "Peptide derivative cytochrome inhibit enzyme system oxidation burst phagocyte cell inflammation disease" <i>DATABASE WPI/DERWENT (Abstract)</i> (1989).
Att	Mavligit, et al., "peniec Versus Hepatic Artery Infusion of Interleukin-2 in Patients with Liver Metastases," <i>Journal of Clinical Oncology</i> , 8: No. 2, 319-324, 1990.
Att	Mertens, et al., "Sustained Indomethacin and Ranitidine with Intermittent Continuous Infusion Interleukin-2 in Advanced Malignant Melanoma: A Phase II Study," <i>Clinical Oncology</i> , 5: No. 2, 107-113, 1993.
Att	Middleton, et al., "Effects of Flavonoids on Immune and Inflammatory Cell Functions," <i>Biochemical Pharmacology</i> , 43: No. 6, 1167-1179, 1992.
Att	Munakata, et al., "Induction of Interferon- Production by Human Natural Killer Cells Stimulated by Hydrogen Peroxide," <i>The Journal of Immunology</i> , 134: No. 4, 2449-2455, April 1985.

EXAMINER	Amel L. Hellstrand	DATE CONSIDERED	4/14/2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 608; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

JAN 07 2005

SHEET 5 OF 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. FENMASHM.28C3	APPLICATION NO. Unknown 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
A2H	Nabil Hanna, "The Role of Natural Killer Cells in the Control of Tumor Growth and Metastasis," <i>Biochimica et Biophysica Acta</i> , 780: 213-226, 1985.
A2H	Nair, et al., "Histamine-Induced Suppressor Factor Inhibition of NK Cells: Reversal with Interferon and Interleukin 2," <i>The Journal of Immunology</i> , 136: No. 7, 2456-2462, April 1, 1986
attached	Novogrodsky, et al., "Hydroxyl radical scavengers inhibit lymphocyte mitogenesis" <i>Proc. Natl. Acad. Sci. USA</i> , 79:1171-1174 (1982).
A2H	Okamoto, et al., "Possible involvement of adenosine 3':5'-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells," <i>Immunology</i> , 70: 186-190, 1990
A2H	Osbond, et al., "Successful Tumour Immunotherapy with Cimetidine in Mice," <i>The Lancet</i> , No. 8221, 1: 636-638 (1981).
A2H	Østensen, et al., "Enhancement of Human Natural Killer Cell Function by the Combined Effects of Tumor Necrosis Factor or Interleukin-1 and Interferon- or Interleukin-2," <i>Journal of Biological Response Modifiers</i> , 8: 53-61, 1989.
A2H	Phillips, et al., "Activation of Natural Killer Cells via the p75 Interleukin 2 Receptor," <i>J. Exp. Med.</i> , 170: 291-296, July 1989.
A2H	Pignol, et al., "Role of Flavonoids in the Oxygen-Free Radical Modulation of the Immune Response," <i>Plant Flavonoids in Biology & Medicine II: Biochemical, Cellular . . .</i> , 173-182, 1988.
A2H	Rabilloaud, et al., "Deficiency in Catalase Activity Correlates with the Appearance of Tumor Phenotype in Human Keratinocytes," <i>Int. J. Cancer</i> , 45: 952-956, 1990.
A2H	Richtsmeier, et al., "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," <i>Ann Otol Rhinol Laryngol</i> , 96: No. 5, 569-572, 1987.
A2H	Rosenberg, "The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-2," <i>Annals of Surgery</i> , 208: No. 2, 121-135, August 1988.
A2H	Roth, et al., "Inhibition of Lymphokine-activated Killer Cell Function by Human Alveolar Macrophages," <i>Cancer Research</i> , 49: 4690-4695, September 1989.
A2H	Saarloo, et al., "Effects of Cancer Immunotherapy with Indomethacin and Interleukin-2 on Murine Hemopoietic Stem Cells," <i>Cancer Research</i> , 52: 6452-6462, December 1, 1992.
A2H	Saarloo, et al., "Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis," <i>Clin. Exp. Metastasis</i> , 11: 275-283, 1993.
A2H	Salup, et al., "Chemoimmunotherapy of Metastatic Murine Renal Cell Carcinoma Using Flavone Acetic Acid and Interleukin 2," <i>The Journal of Urology</i> , 147: 1120-1123, April 1992.
A2H	Schantz, et al., "A phase II study of interleukin-2 and interferon-alpha in head and neck cancer," <i>Investigational New Drugs</i> , 10: 217-223, 1992.
A2H	Schleimer, et al., "Regulation of Human Basophil Mediator Release by Cytokines," <i>The Journal of Immunology</i> , 143: No. 4, 1310-1317, August 15, 1989.
A2H	Seaman, et al., "Suppression of Natural Killing in Vitro by Monocytes and Polymorphonuclear Leukocytes," <i>The Journal of Clinical Investigation</i> , 69: 876-888, April 1982.

EXAMINER	Amel Hellstrand	DATE CONSIDERED	4/14/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

JAN 07 2005

SHEET 6 OF 6

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKER NO. MAXIM, PCS TRADEMA	APPLICATION NO. Unknown 10/076, 306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Hellstrand, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE February 12, 2002	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Arth	Shau, et al., "Inhibition of Lymphokine-Activated Killer- and Natural Killer-Mediated Cytotoxicities by Neutrophils," <i>The Journal of Immunology</i> , 143: No. 3, 1066-1072, August 1989.
Arth	Siegel, et al., "The IL-2 Receptor Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities," <i>Science</i> , Volume 238, October 2, 1987
Arth	Sleijfer, et al., "Phase II Study of Subcutaneous Interleukin-2 in Unselected Patients With Advanced Renal Cell Cancer on an Outpatient Basis," <i>Journal of Clinical Oncology</i> , 10: No. 7, 1119-1123, July 1992.
Arth	Sone, et al., "Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients" <i>Cancer Immunol Immunother</i> , 30:357-362 (1990).
Arth	Stoter, et al., "Sequential Administration of Recombinant Human Interleukin-2 and Dacarbazine in Metastatic Melanoma: A Multicenter Phase II Study," <i>Journal of Clinical Oncology</i> , 9: No. 9, 1687-1691, September 1991.
Arth	Suthanthiran, et al., "Hydroxyl radical scavengers inhibit human natural killer cell activity," <i>Nature</i> 307: 276-278, (1984).
Arth	Szatrowski, et al., "Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells," <i>Cancer Research</i> , 51: 794-798, February 1991.
Arth	Tel-Or, et al., "Hydeoperoxide Metabolism in Cyanobacteria," <i>Archives of Biochemistry and Biophysics</i> , 246: No. 1, 396-402, April 1986.
Arth	Thompson, et al., "Prolonged Continuous Intravenous Infusion Interleukin-2 and Lymphokine-Activated Killer-Cell Therapy for Metastatic Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 6, 960-968, June 1992.
Arth	Thornes, et al., "Combination of Cimetidine with other Drugs for Treatment of Cancer," <i>New England Journal of Medicine</i> 308: 591-592, March 10, 1983.
Arth	Tom Smith, MD, "Histamine Type 2-Receptor Antagonists and Cancer Immunotherapy," <i>Comprehensive Therapy</i> , 16: No. 1, 8-13, 1990.
Arth	Trager, et al., "Immunological Effects of Flavone Acetic Acid," <i>Cancer Research</i> , 50: 6483-6485, October 15, 1990.
Arth	Urba, et al., "Enhancement of Natural Killer Activity in Human Peripheral Blood by Flavone Acetic Acid," <i>The Journal of the National Cancer Institute</i> , 80: No. 7, 521-525, June 1, 1988.
Arth	Weiss, et al., "A Randomized Phase II Trial of Continuous Infusion Interleukin-2 or Bolus Injection Interleukin-2 Plus Lymphokine-Activated Killer Cells for Advanced Renal Cell Carcinoma," <i>Journal of Clinical Oncology</i> , 10: No. 2, 275-281, February 1992.
Arth	Whitacre, et al., "Oxygen Free Radical Generation and Regulation of Proliferative Activity of Human Mononuclear Cells Responding to Different Mitogens," <i>Cellular Immunology</i> , 144: 287-295, 1992.
Arth	Wiltrot, et al., "Flavone-8-Acetic Acid Augments Systemic Natural Killer Cell Activity and Synergizes with IL-2 for Treatment of Murine Renal Cancer," <i>The Journal of Immunology</i> , 140: No. 9, 3261-3265, May 1, 1988.

S:\DOCS\IJM\IJM-3822.DOC

051500

S:\DOCS\WMD\WMD-2500.DOC

021202

EXAMINER	DATE CONSIDERED
<i>Arth</i>	4/14/2005
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	